Drug used in fighting breast, lung, and other cancers
POPULARITY
20 episodes with iressa
26 episodes with iressa
2 episodes with iressa
5 episodes with iressa
With new Pod this week, we're re-releasing the 2nd episode from way back in 2017 that provides a historical overview of how the use of EGFR TKIs changed from their use in all NSLCLC to only with activating mutations.
Saila was diagnosed with stage IV non-small cell lung cancer in June 2017. After her diagnosis at another hospital, she transferred to Dana-Farber for treatment. Saila's treatment currently includes a clinical trial of alternating Tagrisso and Iressa.In her spare time, Saila is an athlete. Whether she is running for miles, competing in triathlons, or practicing yoga, Saila loves to work out. She also finds her happy place when cooking, drinking wine, and spending time with her friends and family.Throughout her diagnosis, Saila has been supported by her mother, Arja, father, Markku, and younger brother, Jesse.Saila originally chose to be treated at Dana-Farber because she likes that its sole mission is cancer research and treatment. She was also driven to Dana-Farber because of Dr. Pasi Janne and his research in the field. Saila started a foundation, JAKSAA, to raise awareness and support fundraising for Dr. Janne's research efforts. Over the last year, Saila has raised about $100,000 for the organization.Dr. Pasi Janne is the director of the Lowe Center for Thoracic Oncology and the Scientific Director of the Belfer Center for Applied Cancer Science. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer.He was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer.
Discussion of gefitinib's journey back to the market and lessons to be learned from it by oncology pharmacist & educator John Bossaer.
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
Today in FirstWord:
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
完整文稿请关注周末微信或登录以下网址： http://english.cri.cn/7146/2014/06/20/2582s832625.htm This is NEWS Plus Special English. I'm Mark Griffiths in Beijing. Here is the news. China's drug administration has warned consumers not to purchase illegally imported cancer drugs online, as most of the drugs are fake. The latest circular issued by the China Food and Drug Administration says the authority found that "Iressa", and some other cancer drugs that were claimed to be imported from India, were being sold online at a price around one-tenth that of legal drugs of the same kind. The administration investigated the cases and found that the drugs were not licensed by the administration, and most of these products were fake drugs produced in China at illegal production sites. There are also drugs that were purchased by unqualified individuals from inauthentic sources abroad and illegally imported to China. The administration warned consumers not to buy these fake drugs and noted that the sale of all kinds of cancer drugs requires a doctor's prescription; and selling prescription drugs online is forbidden. This is NEWS Plus Special English. The Chinese mainland saw only 9 blood donations per 1,000 people last year, below the WHO-proposed minimum ratio for a country's clinical use. China's health watchdog, the "National Health and Family Planning Commission", made the comment recently ahead of World Blood Donor Day, which fell on June 14th. The commission says in a statement that the mainland's blood donation situation is "not compatible" with its economic and social development. Hong Kong and Macao recorded 30 and 23 donations per 1,000 people respectively last year, while the figure in developed countries usually stands at 40. The WHO recommends 10 to 30 donations per 1,000 people to meet China's clinical demand. Though lagging behind developed countries and regions, the number of blood donors in the mainland rose 260-fold last year to almost 13 million from only 50,000 in 1998. The Chinese government has set a goal of raising the ratio to 10 donations per 1,000 people by the end of next year. Achieving the goal requires an annual increase of at least 2.5 percent in blood donors, but the number only edged up 1.8 percent over the last year. You're listening to NEWS Plus Special English. I'm Mark Griffiths in Beijing. An overnight session watching the FIFA World Cup may have caused the death of a 25-year-old man in the eastern Chinese city of Suzhou. A local hospital says the young man was found dead in his room early in the morning on June 14th with his Television still airing a football match. Doctors in the hospital suspected his death was linked to staying up late watching the games, which are aired live in the middle of the night in China due to the time difference with tournament host country Brazil. Although doctors did not specify what exactly may have caused this fatality, exhaustion or a heart attack are possible factors. They warned football fans to be cautious about their health while watching the world cup. China may not be represented at this year's FIFA World Cup, but Chinese football fans have nevertheless been staying up late at night to watch matches broadcast from midnight to 6 a.m. Beijing Time. This is NEWS Plus Special English. If the World Cup in Brazil fails to woo you as a travel destination, and if you have 600,000 yuan, around 97,000 US dollars to spare, then consider space travel. Via "Taobao.com", China's wealthy people can now book a private trip into space, though just for five to six minutes. Orders have opened to book a trip with the Dutch firm Space Expedition, and more than 300 buyers purchased trips in the first minutes after the registration began. Four entrepreneurs from Chengdu in southwestern China and two from Shanghai are among those who signed up for the trip into space. The modules differ in terms of flight length and departure time. The "Pioneer Astronaut" program allows travelers to fly around 60 kilometers into space starting in the fourth quarter of next year. Buyers can also sign up for premium travel packages such as the "Founder Astronaut" trip for 1.4 million yuan; or pay 630,000 yuan for the "Future Astronaut" program. Both flights start in 2016 and will take travellers as high as 100 kilometers above the earth. This is NEWS Plus Special English. You're listening to NEWS Plus Special English. I'm Mark Griffiths in Beijing. You can access our program by logging onto NEWSPlusRadio.cn. You can also find us on our Apple Podcast. If you have any comments or suggestions, please let us know by e-mailing us at mansuyingyu@cri.com.cn. That's mansuyingyu@cri.com.cn. Now the news continues. The Chinese version of the Disney musical "The Lion King" will be staged at the yet-to-be completed Shanghai Disney Resort. The Chinese-language musical will stay true to the original English version. It will be performed at the 1,200-seat Walt Disney Theater in the resort. The show will start recruiting local actors this summer. Shanghai Disneyland is scheduled to open at the end of next year. It is the first Disney resort on the Chinese mainland. Shanghai Disneyland has two themed hotels, a large retail, dining and entertainment venue, as well as an array of recreational facilities. It has been designed to combine Chinese elements with Disneyland traditions. The resort is a joint venture between the Walt Disney Company and the Shanghai Shendi Group.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?
Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?
Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?
Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Jack West describes recent information on the probability that someone with a rare EGFR mutation on exon 20, rather than a more common "activating" mutations on exon 19 or 21, will benefit from an oral EGFR inhibitor vs. standard chemotherapy.
Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, focusing here on treatments focusing on the EGFR axis.
Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, focusing here on treatments focusing on the EGFR axis.
Dr. Mario Lacouture, expert dermatologist at Memorial Sloan-Kettering Cancer Center in NYC, answers questions on management of side effects related to skin, hair, and nails for patients on cancer treatments that cause dermatologic complications.
Dr. Mario Lacouture, expert dermatologist at Memorial Sloan-Kettering Cancer Center in NYC, answers questions on management of side effects related to skin, hair, and nails for patients on cancer treatments that cause dermatologic complications.
Dr. Mario Lacouture, expert dermatologist at Memorial Sloan-Kettering Cancer Center in NYC, reviews management of side effects related to skin, hair, and nails for patients on treatments for cancer treatments that cause dermatologic complications.
Dr. Mario Lacouture, expert dermatologist at Memorial Sloan-Kettering Cancer Center in NYC, reviews management of side effects related to skin, hair, and nails for patients on treatments for cancer treatments that cause dermatologic complications.
Dr. Lecia Sequist of Massachusetts General Hospital answers questions about acquired resistance to EGFR tyrosine kinase inhibitors and repeat biopsies of tumors over the course of treatment for advanced NSCLC.
Dr. Lecia Sequist of Massachusetts General Hospital answers questions about acquired resistance to EGFR tyrosine kinase inhibitors and repeat biopsies of tumors over the course of treatment for advanced NSCLC.
Dr. Lecia Sequist of Massachusetts General Hospital describes the results of their experience in repeating biopsies in patients over the course of their ongoing treatment for advanced NSCLC and the changes in tumor characteristics over time.
Dr. Lecia Sequist of Massachusetts General Hospital describes the results of their experience in repeating biopsies in patients over the course of their ongoing treatment for advanced NSCLC and the changes in tumor characteristics over time.
Dr. Lecia Sequist of Massachusetts General Hospital presents a summary of the challenge of acquired resistance to EGFR tyrosine kinase inhibitors like Tarceva (erlotinib) and Iressa (gefitinib), along with emerging ideas for overcoming it.
Dr. Lecia Sequist of Massachusetts General Hospital presents a summary of the challenge of acquired resistance to EGFR tyrosine kinase inhibitors like Tarceva (erlotinib) and Iressa (gefitinib), along with emerging ideas for overcoming it.
© 2020-2025 Ivy Podcast Discovery LLC
